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ABSTRACT
Kif7 is a ciliary kinesin motor protein that regulates mammalian Hedgehog 
pathway activation through influencing structure of the primary cilium. Here we show 
that Kif7 is required for normal T-cell development, despite the fact that T-cells lack 
primary cilia. Analysis of Kif7-deficient thymus showed that Kif7-deficiency increases 
the early CD44+CD25+CD4-CD8- thymocyte progenitor population but reduces 
differentiation to CD4+CD8+ double positive (DP) cell. At the transition from DP 
to mature T-cell, Kif7-deficiency selectively delayed maturation to the CD8 lineage. 
Expression of CD5, which correlates with TCR signal strength, was reduced on DP and 
mature CD4 and CD8 cells, as a result of thymocyte-intrinsic Kif7-deficiency, and Kif7-
deficient T-cells from radiation chimeras activated less efficiently when stimulated 
with anti-CD3 and anti-CD28 in vitro. Kif7-deficient thymocytes showed higher 
expression of the Hedgehog target gene Ptch1 than WT, but were less sensitive to 
treatment with recombinant Shh, and Kif7-deficient T-cell development was refractory 
to neutralisation of endogenous Hh proteins, indicating that Kif7-deficient thymocytes 
were unable to interpret changes in the Hedgehog signal. In addition, Kif7-deficiency 
reduced cell-surface MHCII expression on thymic epithelial cells.
INTRODUCTION
The thymus is an essential specialised environment 
for the production of T-cells, in which thymic epithelial 
cells (TEC) provide cell surface interactions and secreted 
factors required for T-cell development, including 
Hedgehog proteins [1-5]. Here we investigate the function 
in T-cell development of the kinesin motor protein Kif7, a 
regulatory molecule of the mammalian Hh pathway [6-8].
Kif7 is vertebrate homologue of Drosophila Costal 
2 (Cos2)[9-11]. In Drosophila, Hh signals by binding to its 
cell surface receptor Patched (Ptch), which then releases 
the signal transduction molecule Smoothened (Smo) to 
transduce the signal and activate the transcription factor 
Ci. Cos2 binds the cytoplasmic tail of Smo and is essential 
to regulate the activity of Ci. Although many aspects of 
Hh signalling are highly conserved between Drosophila 
and vertebrates, including the functions of mammalian 
Ptch1, Smo and the Ci orthologues, Gli1, Gli2 and Gli3, 
one major difference is that canonical Hh signalling in 
mammalian cells involves localisation and movement of 
the signal transduction machinery in the primary cilium 
[12]. Mammalian Smo has lost its binding site for Kif7 on 
its cytoplasmic tail, but although initial reports suggested 
that Kif7 was not involved in Hh signalling in mammalian 
cells, analysis of Kif7-deficient mice has shown that Kif7 
is required to regulate Hh pathway activation, and that 
it can act as both a positive or negative regulator [7, 8, 
11]. Kif7 localizes in the tip of the primary cilium and 
is believed to regulate Gli activity by controlling cilium 
structure [6]. 
In the thymus, Shh promotes TEC differentiation, 
and mTEC lineage choice [13]. Hh signalling also 
promotes the earliest stages of T-cell development [5, 14], 
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but negatively regulates pre-TCR induced differentiation 
from CD4-CD8- double negative [15] to CD4+CD8+ 
double positive (DP) cell[16, 17], and negatively regulates 
differentiation from CD4+CD8+ double positive (DP) to 
mature CD4 single positive (SP) and CD8 SP cell [18-20]. 
Here we examine the role of Kif7 in T-cell and TEC 
development in the fetal thymus. T-cells can transduce 
Hh signals[21], but they lack primary cilia, although they 
express components of the ciliary transport machinery, 
which are involved in the immune synapse [22, 23]. It is 
therefore unclear if Kif7 will be necessary for Hh pathway 
regulation in the absence of primary cilia in T-cells. Here, 
we show that Kif7-deficient thymocytes are less sensitive 
to external modulation of physiological Hh signals 
than WT thymocytes. We show that in the embryonic 
thymus Kif7-deficiency increases the CD44+CD25+ DN 
population, which is the developmental stage at which 
progenitor cells specify to the T-cell fate. Additionally, 
Kif7 is required for normal differentiation from DN 
to DP cell, and influences cell surface CD5 expression, 
differentiation from DP to mature CD8SP cell, and 
MHCII-expression by TEC. 
RESULTS
Kif7 is expressed in the thymus and developing 
thymocytes
To investigate the role of Kif7 in the regulation 
of T-cell development, we analysed Kif7 expression 
in whole thymus and facs-sorted adult thymocyte 
subsets by quantitative(Q) RT-PCR. During thymocyte 
development, cells pass through well-defined stages: DN 
cells must rearrange the TCRβ locus to express the pre-
TCR complex, and require pre-TCR signal transduction 
to differentiate into DP cells. They must then rearrange 
the TCRα locus, and require TCR signal transduction to 
differentiate from DP to mature CD4SP and CD8SP cell. 
The DN population can be subdivided by expression to 
CD44 and CD25. CD44+CD25- (DN1) cells, differentiate 
to CD44+CD25+ (DN2), then to CD44-CD25+ (DN3), 
then, after pre-TCR signal transduction to the CD44-
CD25- (DN4) population, which progresses to the DP 
stage, sometimes via an immature CD8+ intermediate 
(ISP)[4]. We therefore sorted the four DN subsets, in 
addition to DP, CD4SP and CD8SP populations. Despite 
the fact that thymocytes lack primary cilia, we detected 
Kif7 expression in RNA prepared from all thymocyte 
subsets throughout T-cell development, as well as the 
whole thymus. We found relatively low expression in the 
DN1 population and expression was up-regulated in DN2 
and DN3 populations, with peak expression in DN4 cells, 
and down-regulation in DP and SP populations (Figure 
1A). 
T-cells develop normally in the Kif7-heterozygous 
thymus
Kif7-/- embryos die in utero with severe 
developmental defects, but Kif7+/- mice develop normally 
and appear normal[8]. We therefore compared the adult 
Kif7+/- thymus with Kif7+/+ [24]. The number of 
thymocytes was similar between Kif7+/- and WT mice 
(Figure 1B), and we found no significant differences in 
the proportion of, or number of cells in the DN subsets, 
DP or mature SP populations between WT and Kif7+/- 
(Figure 1C-1F). 
We then examined cell surface expression of CD5, 
CD69 and CD24. CD5 is a negative regulator of TCR 
signalling and level of cell surface CD5 expression 
correlates with TCR signal strength[25, 26]. CD69 is an 
activation marker that is expressed during TCR repertoire 
selection following TCR signal transduction, and CD24 
(HSA) is a maturation marker that is down-regulated 
as developing T-cells become more mature[27, 28]. DP 
thymocytes express high levels of CD24 and then acquire 
CD69 expression as a result of TCR signalling for positive 
selection. Newly positively-selected SP thymocytes also 
express high levels of CD24 and CD69, and as they mature 
they down-regulate both CD24 and CD69. Therefore, 
to determine maturation status and estimate TCR signal 
strength in the DP and SP populations, we measured 
expression of CD5, CD69 and CD24. No differences were 
detected in Kif7+/- DP, CD4SP and CD8SP populations 
compared to WT (Figure 1G). 
We also examined T-cell populations in WT 
and Kif7+/- spleen and lymph node [29]. We found no 
differences in the number of cells in the spleen or LN 
between WT and Kif7+/-, or in the proportion or numbers 
of CD4 and CD8 T-cells in either tissue (Figure 1H-1M). 
This analysis therefore indicates that loss of one 
copy of Kif7 is dispensable for adult T-cell development.
Kif7 regulates early thymocyte development and 
differentiation from DN to DP in the fetal thymus
Next, to determine the effect of Kif7-deficiency on 
T-cell development, we examined T-cell development in 
WT, Kif7+/- and Kif7-/- E16.5 fetal thymus. We analysed 
E16.5 because this is the day of development when DP 
cells first appear, and because we observed highest Kif7 
expression in the DN4 subset, which are making the pre-
TCR induced transition from DN3 to DP cell. Thymocyte 
numbers in Kif7-/- embryos were reduced significantly, 
with on average 50% fewer cells than in WT littermates 
(Figure 2A). Analysis of the DN populations revealed a 
significant increase in the percentage and number of DN2 
cells in Kif7-/- compared to WT (Figure 2B-2D). The DN2 
population contains the first cells that are committed to the 
T-cell lineage, and differentiation and expansion of this 
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Figure 1: Thymocytes develop normally in Kif7+/- mice. In all bar charts in this figure, error bars show the standard error of 
the mean (SEM). A. Bar chart shows Kif7 transcript levels in FACS sorted DN, DP, SP thymocytes and the whole thymus assessed by 
quantitative RT-PCR. The expression levels were normalized against Hprt. B.-G. Analysis of developing thymocytes, isolated from WT (n 
= 6) and Kif7+/- (n = 6) mice at 6-8 weeks old. B. Scatter plot: number of cells in the thymus. Each data point represents a single mouse. 
The mean for each group is indicated with a line. C. Dot plots: flow cytometry profiles of DN subpopulations (DN1-DN4) by surface 
expression of CD44 and CD25 gated on CD4-CD8- cells. D. Mean number of cells in DN1-DN4 subsets in WT and Kif7+/- is shown in bar 
chart. Percentages of thymocyte subsets (mean+/-SEM): DN1, WT: 2.74+/-0.83 KO:1.75+/-0.34; DN2, WT: 7.46+/-1.72 KO:7.11+/-2.4; 
DN3, WT: 36.6+/-2.67 KO:34.2+/-3.68; DN4, WT: 53.2+/-4.3 KO:56.9+/-5.65. There were no significant differences in the percentage 
of thymocyte subsets. E. Dot plots: flow cytometry of anti-CD4 and anti-CD8 staining on Kif7+/- and WT thymus, giving percentage of 
DP, CD4SP, CD8SP cells. F. Mean number of cells in DP, CD4SP and CD8SP populations in WT and Kif7+/- thymus is shown in bar 
chart. Percentages of DP, CD4SP and CD8SP populations (mean+/-SEM): DP, WT: 84.1+/-1.09 KO:81.2+/-0.98; CD4SP, WT: 6.61+/-0.76 
KO:8.02+/-0.54; CD8SP, WT: 2.54+/-0.27 KO:2.81+/-0.38. There were no significant differences in the percentage of T-cell populations. 
G. Histograms show cell surface anti-CD5 (upper panel), anti-CD69 (middle panel) and anti-CD24 (lower panel) staining, gated on DP, 
CD4SP and CD8SP populations in WT and Kif7+/- thymus. H.-J. Analysis of T-cells in spleen, isolated from WT (n = 6) and Kif7+/- (n 
= 6) mice at 6-8 weeks old. H. Scatter plot: number of cells in the spleen. Each data point represents a single mouse. The mean for each 
group is indicated with a line. I. Dot plots: flow cytometry of anti-CD4 and anti-CD8 staining on Kif7+/- and WT spleen, giving percentage 
of CD4 T-cells and CD8 T-cells. J. Mean number of cells in CD4 and CD8 T-cell populations in WT and Kif7+/- spleen is shown in bar 
chart. Percentages of CD4 and CD8 T-cell populations (mean+/-SEM): CD4 T-cell, WT: 14.2+/-1.29 KO:15.2+/-0.79; CD8 T-cell, WT: 
7.7+/-0.60 KO:8.19+/-0.45 There were no significant differences in the percentage of T-cell populations. K. Scatter plot: number of cells 
in the two inguinal lymph nodes. Each data point represents a single mouse. The mean for each group is indicated with a line. L. Dot plots: 
flow cytometry of anti-CD4 and anti-CD8 staining on Kif7+/- and WT lymph node, giving percentage of CD4 T-cells and CD8 T-cells. M. 
Mean number of cells in CD4 and CD8 T-cell populations in WT and Kif7+/- LN is shown in bar chart. Percentages of CD4 and CD8 T-cell 
populations (mean+/-SEM): CD4 T-cell, WT: 37.9+/-1.40 KO:39.6+/-1.51; CD8 T-cell, WT: 25.6+/-0.85 KO:25.4+/-0.63. There were no 
significant differences in the percentage of T-cell populations.
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Figure 2: Increased DN2 population but impaired DN to DP transition in E16.5 Kif7-/- embryos. In all bar charts in this 
figure, error bars show the standard error of the mean (SEM). A.-H. Analysis of developing thymocytes, isolated from E16.5 WT (n = 6), 
Kif7+/-(n = 16) and Kif7-/- (n = 7) fetal thymus. A. Scatter plot: thymocyte number in the fetal thymus. Each data point represents a single 
embryo. The mean for each group is indicated with a line. (*p = 0.03, WT versus Kif7-/-) B. Dot plots: flow cytometry profiles of DN 
subsets (DN1-DN4) by the surface expression of CD44 and CD25, gated on CD4-CD8- thymocytes, giving the percentage in each quadrant. 
C. Bar chart: mean relative percentage of DN1-DN4 subsets of the DN population. Each embryo was compared to its own littermates, and 
to allow comparison between litters for each embryo, for each subset, the relative percentage was calculated by dividing by the mean of 
the WT value for that litter; for DN2, *p = 0.02, WT versus Kif7-/-. D. Bar chart shows absolute number of cells in each DN thymocyte 
populations, relative to mean number of cells in that population from WT littermate embryos, in order to allow comparison between litters, 
where gestational age may vary by up to 12 hours; for DN2, *p = 0.045 WT versus Kif7-/-. E. Dot plots: flow cytometry profiles show anti-
CD4 and anti-CD8 staining, gated on CD3-, to identify ISP and DP populations. The percentage of cells in each quadrant is given. F. Bar 
chart: mean percentage of ISP and DP populations (gated on CD3-); for ISP *p = 0.03; DP **p = 0.002, WT versus Kif7-/-. G. Bar chart: 
mean ratio of DP:ISP (relative to mean of WT). (**p = 0.003, WT versus Kif7-/-). H. Dot plots: flow cytometry of SSC and anti-CD3, 
gated on CD8+ cells giving the percentage of CD3+ cells. I. Left-hand bar chart: mean relative percentage of CD3+ cells, gated on CD8+; 
**p = 0.004, WT versus Kif7-/-. Right-hand bar chart: mean number of CD3+ cells (gated on CD8+), relative to mean of number from WT 
littermates; **p = 0.007, WT versus Kif7-/-. J.-K. Analysis of thymocytes isolated from E18.5 WT (n = 3), Kif7+/- (n = 3) and Kif7-/- (n 
= 3) littermate fetal thymus. Number of thymocytes (mean+/-SEM): WT 3.1 x106 +/- 5.0 x 105; Kif7+/- 3.2 x 106 +/- 4.3 x 105; Kif7-/- 2.8 
x 106 +/- 2.6 x 105; there were no significant differences in the number of thymocytes. J. Dot plot: flow cytometry profiles of anti-CD4 and 
anti-CD8, giving percentage in each quadrant. K. Bar chart shows mean percentage of cells in DP, CD4SP and CD8SP populations. 
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population is promoted by Hh signalling [3, 5, 14, 17], 
suggesting that Kif7 may function to negatively regulate 
the Hh signal at this developmental stage. 
At the transition from DN3 to DP cell, the 
proportions of CD8ISP and DP populations were 
significantly reduced in Kif7-/- compared to WT 
littermates (Figure 2E-2F), and the ratio of DP:ISP cell 
was significantly reduced by 50% compared to WT 
(Figure 2G), indicating that the transition from ISP to DP 
was impaired. 
Expression of cell surface CD3 is essential for 
TCR signalling and cell surface CD3 is up-regulated after 
pre-TCR signalling, as thymocytes rearrange the TCRα 
locus and express the cell surface TCR/CD3 complex. 
We measured cell surface expression of CD3 on CD8+ 
thymocytes (DP and ISP and CD8SP) and found that the 
proportion and number of CD3+ cells in the Kif7-/- thymus 
was significantly reduced compared to WT, typically to 
2.26% in Kif7-/- compared to 5.02% in WT (Figure 2H-
2I). In contrast, we found no significant differences in the 
Kif7+/- thymus compared to WT, indicating that one copy 
of Kif7 was sufficient to maintain homeostasis during 
T-cell development in the fetal thymus, as in the adult 
thymus. 
On E18.5, the DP population in the Kif7-/- thymus 
had recovered and was similar to WT, indicating that DP 
cells could survive and accumulate (Figure 2J-2K). 
Reduced differentiation from DP to CD8SP in 
Kif7-/- thymus
To investigate the influence of loss of Kif7 on later 
stages of T-cell development, we cultured E16.5 fetal 
thymus organ cultures (FTOC), and compared Kif7-/- 
with their WT littermates. This enabled us to investigate 
the transition from DP to SP cell as SP cells first arise, 
in a more or less synchronised wave. After 7 days in 
FTOC, we found similar thymocyte numbers in Kif7-/- 
compared to WT (Figure 3A). Analysis of the thymocyte 
subsets showed the CD8SP population in Kif7-/- was 
significantly reduced, whereas the proportion of ISP cells 
was significantly increased (Figure 3B-3D). Following the 
7-day culture period, the DP population had recovered in 
the Kif7-/- FTOC, again indicating that these cells were 
able to survive and accumulate, and consistent with the 
phenotype of the E18.5 thymus. The mean proportion of 
CD3hiDP cells increased in the Kif7-/- compared to WT, 
and it therefore appeared that DP cells accumulated at 
the transition from DP to SP, because the development of 
mature CD8SP cells was partially arrested. 
We therefore compared the ratio of DP:CD4SP, 
DP:CD8SP, DP:SP and CD4SP:CD8SP in Kif7-/- FTOC 
from individual embryos to WT counterparts. Both 
DP:CD8 and DP:SP ratios in the Kif7-/- were significantly 
increased by 75% and 49% respectively, compared to WT 
(Figure 3E). Moreover, the CD4:CD8 ratio was increased 
by 50% in Kif7-/- FTOC (Figure 3E). The increase in 
the DP:CD8 and CD4:CD8 ratio in the Kif7-/- FTOC 
suggested that Kif7 promotes CD8-lineage differentiation. 
As differentiation to the CD8 lineage generally requires 
weaker and shorter duration of TCR signalling than 
differentiation to CD4-lineage, we then examined cell 
surface CD5, as a measure of TCR signal strength (Figure 
3F-3G). We found significantly reduced CD5 expression in 
Kif7-/- DP compared to WT littermates. Gating on CD3hi 
cells showed that average MFI of CD5 was lowest on the 
CD8SP population, intermediate in DP cells, and highest 
on the CD4SP population in WT and Kif7-/- (Figure 3F). 
Mean MFI of anti-CD5 staining was significantly lower in 
all populations on Kif7-/- than on their WT counterparts, 
and with greater differences in DP and CD8SP than 
CD4SP (Figure 3F-3G). 
We then cultured Kif7-/- E18.5 FTOC, in order 
to investigate the impact on SP populations after 
they first appear (Figure 3H-3J). The proportion of 
thymocyte populations in Kif7-/- FTOC was similar 
to WT, suggesting a delay rather than arrest in CD8SP 
differentiation. 
Kif7-/- thymocytes are refractory to modulation of 
external Hh signals
The Kif7-deficient embryo displays a similar 
phenotype to the Gli3-deficient embryo suggesting that, 
like Gli3, Kif7 plays a predominantly negative regulatory 
role in Hh signalling [8]. However, further investigations 
showed that Kif7 is a core modulator, which is also 
required for Shh activation by organizing the cilium 
architecture [6]. 
We therefore tested if Kif7-/- thymocytes could 
respond to Shh treatment. We treated WT, Kif7+/- and 
Kif7-/- FTOC with recombinant Shh (rShh) for 7 days and 
assessed expression of the Hh target gene, Ptch1 by QRT-
PCR in thymocyte cell suspensions (>98% purity) prepared 
from the FTOC, in three independent experiments. We 
found that Ptch1 expression was significantly higher in 
the control Kif7-/- cultures compared to WT, whereas 
Ptch1 expression in Kif7+/- cultures was not significantly 
different from WT (Figure 4A). Ptch1 expression was 
up-regulated significantly in rShh-treated WT and Kif7+/- 
FTOC compared to untreated control, but interestingly, 
Ptch1 expression was not up-regulated in rShh-treated 
Kif7-/- FTOC compared to untreated Kif7-/- control 
(Figure 4A-4B). Thus, although Kif7-/- cells had higher 
levels of Ptch1 initially, they seemed refractory or less 
sensitive to Hh pathway activation, suggesting that the 
influence of Kif7-deficiency was cell intrinsic. 
We then tested the hypothesis that Kif7-/- 
thymocytes are refractory to modulation of external 
Hh signals by inhibiting the physiological Hh signal in 
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Figure 3: SP development in Kif7-/- FTOC. In all bar charts in this figure, error bars show the standard error of the mean (SEM). 
A.-G. Analysis of E16.5 WT (n = 26) and Kif7-/- (n = 14) FTOC cultured for 7 days. A. Scatter plot: cell number in E16.5 WT and Kif7-/- 
FTOC after 7 days in culture. Each data point represents a single thymus. The mean for each group is indicated with a line. B. Dot plot: flow 
cytometry of anti-CD4 and anti-CD8, showing percentage of DP, CD4SP and CD8SP thymocytes. C. Dot plot: flow cytometry of anti-CD4 
and anti-CD8, gated on CD3hi cells, giving percentage of cells in each quadrant. D. Left-hand bar chart shows mean relative percentages of 
DN, ISP, CD3hiDP, CD4SP, and CD8SP populations; for CD8ISP,*p = 0.04; for CD3hiDP, *p = 0.026; for CD8SP, *p = 0.03. Right-hand 
bar chart shows mean absolute number of cells in each populations (relative to mean of WT littermates); for CD8SP,***p<0.001 E. Bar 
chart: mean relative thymocyte subset ratios (ratio relative to mean of WT ratio from the same litter); CD4:CD8, *p = 0.045; DP:CD8; *p 
= 0.01; DP:SP, *p = 0.04. F. Scatter plot shows MFI of anti-CD5 staining on DP, CD4SP and CD8SP populations from WT (solid circles, 
n = 11) and Kif7-/- (open circles, n = 12) FTOC. Each point represents an individual thymus. Lines show mean MFI. For both WT and 
Kif7-/- thymus, differences between DP, CD4SP and CD8SP were significant (p < 0.001) G. Bar chart: mean of relative MFI of anti-CD5 
staining (relative to mean of WT littermate MFI for that population), gated on CD3hi, in DP, CD4SP and CD8SP populations; for DP, *p = 
0.04; CD4, *p = 0.01; CD8, *p = 0.02. H.-J. Analysis of E18.5 WT (n = 5) and Kif7-/- (n = 3) FTOC cultured for 7 days. H. Scatter plot: 
number of cells in the thymus, the line shows the mean. Differences were not significant. I. Dot plots: flow cytometry of anti-CD4 and 
anti-CD8, giving the percentage in each quadrant. J. Left-hand Bar chart shows mean relative absolute number of cells in DP, CD4SP and 
CD8SP populations in WT (solid bars) and Kif7-/- (open bars) (relative to mean of WT littermates). Right-hand bar chart shows relative 
percentage of cells in DP, CD4SP and CD8SP populations, relative to mean percentage in WT littermates. 
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Figure 4: Response of Kif7-/- thymus to Shh- and Hhip-treatment. In all bar charts in this figure, error bars show the standard 
error of the mean (SEM). E16.5 WT and Kif7-/- FTOC cultured with or without rShh or rHhip for 7 days. This experiment was carried out 
independently three times on different occasions (three sets of biological replicates). A. Transcription of Ptch in the E16.5 WT, Kif7+/- and 
Kif7-/- FTOC treated or untreated with rShh assessed by quantitative (Q) RT-PCR. The expression levels were normalized against Hprt. 
Data represent mean of the three independent experiments. (*p = 0.04, untreated WT versus untreated Kif7-/-; **p = 0.007, untreated 
WT versus +rShh WT; *p = 0.04, untreated Kif7+/- versus +rShh Kif7+/-; ns, not significant). B. Mean fold change in Ptch expression 
on rShh treatment (relative to Ptch expression in untreated FTOC of same genotype) in WT, Kif7+/- and Kif7-/- FTOC; *p = 0.041 for 
Kif7+/- versus Kif7-/-. (C-I) WT (n = 6) and Kif7-/- (n = 6) FTOC were cultured with or without rHhip treatment for 7 days. Data are 
from three independent experiments. C. Histograms show CD3 expression on untreated control and rHhip treated Kif7-/- and WT FTOC 
in a representative experiment, giving the percentage of cells in the positive marker. D. Bar chart: the relative mean percentage of CD3hi 
cells on rHhip treatment (relative to mean percentage of CD3hi thymocytes in untreated control FTOC of same genotype); **p = 0.008, 
untreated WT versus WT +rHhip. The difference between untreated Kif7-/- versus Kif7-/- +rHhip was not statistically significant. E. Dot 
plots: CD4 and CD8 staining, gated on CD3hi in WT and Kif7-/- untreated control and rHhip-treated FTOC. The percentages of CD4SP, 
DP and CD8SP are stated in the quadrants. F. The relative mean percentage, gated on CD3hi, of DP, CD4SP and CD8SP populations in 
rHhip-treated FTOC (relative to percentage in untreated control of same genotype) WT (solid bars) and Kif7-/- (open bars); CD4,*p = 0.04; 
CD8, *p = 0.04; untreated WT versus +rHhip WT. G. Dot plots: flow cytometry of SSC versus anti-CD24 staining on CD4SP and CD8SP 
thymocyte populations in WT and Kif7-/- untreated control and rHhip-treated FTOC. The percentage of cells that are CD24hi is given. H. 
and I. Bar charts show the mean percentage of CD24hi cells in untreated control or rHhip-treated WT and Kif7-/- FTOC, for (H) CD4SP 
cells, and (I) CD8SP cells (*p = 0.03, untreated WT versus WT+ rHhip for CD4SP). 
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FTOC by treatment of recombinant Hedgehog-interacting 
protein (rHhip), which binds and neutralises endogenous 
Hh protein in the cultures. Neutralisation of Hh signals in 
FTOC by treatment with neutralising anti-Hh monoclonal 
antibody has previously been shown to promote T-cell 
development, and increase differentiation from CD3hi 
DP to mature SP cell and to increase the CD4SP:CD8SP 
ratio [19, 20]. Hhip-treatment significantly increased 
the proportion of CD3hi thymocytes in the WT FTOC, 
compared to control untreated cultures (Figure 4C-4D). 
As expected, the proportion of CD3hi thymocytes was 
lower in the untreated control Kif7-/- FTOC than WT, 
consistent with the reduction in T-cell development on 
E16.5. Interestingly in three independent experiments, 
Hhip-treatment did not significantly affect the proportion 
of CD3hi cells in the Kif7-/- FTOC (Figure 4D). Gating 
on CD3hi cells, the WT rHhip-treated FTOC showed 
a significant increase in the proportion of CD4SP and 
CD8SP cells, and an increase in the CD4SP:CD8SP ratio 
compared to WT control FTOC. Control Kif7-/- FTOC 
had reduced differentiation from CD3hiDP to CD8SP 
compared to WT (Figure 4E). To examine the influence of 
Figure 5: TEC population in Kif7-/- . In all bar charts in this figure, error bars show the standard error of the mean (SEM). A. 
Expression of Kif7 and related genes assessed by microarray (GSE81433) from sorted cTEC (CD45-EpCam1+Ly51+UEA-1-, upper plot) 
and mTEC (CD45-EpCam1+Ly51-UEA-1+, lower plot) extracted from fetal (crosses) and adult (squares) thymus. (B-I) E16.5 WT (n = 4) 
and Kif7-/- (n = 5) FTOC were cultured for 7 days and TEC analysed by flow cytometry. B. Dot plot shows anti-CD45 and anti-Epcam1 
staining on WT and Kif7-/- FTOC. C. Bar chart: percentage of TEC (CD45-Epcam1+) cells in WT and Kif7-/-. D. Facs profiles and E. 
bar chart shows proportion of cTEC (Ly51+UEA-1-) and mTEC (Ly51-UEA-1+) populations in WT and Kif7-/- FTOC. F. Histograms: 
cell surface staining for MHCI (upper panel) and MHCII (lower panel) on cTEC and mTEC populations isolated from WT (solid grey) 
and Kif7-/- (black line), giving MFI for each population. (G-I) Bar charts show mean percentage of G. MHCIhi cells and H. MHCIIhi cells 
in cTEC and mTEC populations from WT (solid bars) and Kif7-/- (open bars) fetal thymus; for MHCII, cTEC, *p = 0.048; mTEC, *p = 
0.01 I. Bar chart: relative mean MFI (relative to mean of WT littermates) of anti-MHCII staining in cTEC and mTEC within the MHCII+ 
population; cTEC, *p = 0.03; mTEC, *p = 0.01. 
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Kif7 on rHhip-treatment during the transition from DP to 
SP, we compared the proportion of each population in the 
CD3hi gate from the untreated lobe to that of the rHhip-
treated lobe from the same thymus, and calculated the 
relative increase or decrease in each population (Figure 
4F). WT rHhip-treated FTOC showed significant increases 
in the CD4SP and CD8SP populations compared to their 
untreated controls, but rHhip treatment had no significant 
effect on the proportion of DP or mature SP populations 
in the Kif7-/- FTOC. Hhip-treatment reduced cell surface 
expression of the maturation marker CD24 on WT SP 
populations, indicating that not only did Hh-neutralisation 
increase the proportion of SP cells, but also the maturity 
of those cells produced. However, rHhip-treatment had 
no significant effect on CD24 expression in Kif7-/- FTOC 
(Figure 4G-4I). 
Overall, these experiments indicated that T-cell 
development in the Kif7-/- thymus is less sensitive to 
modulation of the external Hh-signal than in WT thymus. 
Kif7 influences TEC
Shh and Gli-family transcription factors are 
expressed in TEC, and Shh promotes TEC development 
and mTEC lineage choice [13, 18, 30]. We therefore 
examined Kif7 expression in microarray datasets from Facs 
sorted cTEC and mTEC populations from fetal and adult 
thymus. We also assessed expression of Sufu and Kif3a, 
which are Hh mediators in the cilia and Kif27, a kinesin 
that is related to Kif7 [31-33]. Kif7 and Sufu are expressed 
at similar levels in the cTEC and mTEC compartments 
in both the fetal and adult thymus. Interestingly, Kif3a is 
highly expressed in fetal TEC and its expression is lower 
in TEC from adult mice, while expression of Kif27 was 
very low/below detection threshold in both fetal and adult 
thymus tissues (Figure 5A).
Given that Kif7 is expressed by TEC as well as 
thymocytes, we examined TEC populations in fetal Kif7-
/- and WT littermate thymus. We cultured E16.5 FTOC for 
5 days, to allow differentiation of both TEC lineages. We 
found no significant difference in the overall number of 
TEC in the thymus, defined as CD45-Epcam1+ cells, or in 
the ratio of mature cTEC (CD45-Epcam1+Ly51+UEA-1-) 
to mature mTEC (CD45-Epcam1+Ly51-UEA-1+) 
populations (Figure 5B-5E). In Shh-/- thymus, both cTEC 
and mTEC express higher levels of cell-surface MHCII 
than WT, whereas Gli3-/- cTEC and mTEC express lower 
levels of cell surface MHCII than WT [13]. We therefore 
compared cell surface expression of MHCI and MHCII in 
cTEC and mTEC from Kif7-/- and WT thymus (Figure 5F-
5I). In both cTEC and mTEC populations, the proportion 
of cells that stained positive with anti-MHCII was higher 
in WT than in Kif7-/-, whereas although the average 
proportion of cells with high cell surface expression of 
MHCI was also reduced in both Kif7-/- TEC populations, 
this difference was not significant (Figure 5F-5I). 
Comparison of the level of cell surface expression (MFI) 
of MHCII in cTEC and mTEC populations, gated on 
MHCII+ cells showed that the level of MHCII expression 
within the positive cells was also lower in Kif7-/- cTEC 
and mTEC populations than in WT. Thus, in the fetal 
thymus, Kif7 also plays a role in TEC, and the Kif7-/- 
TEC populations have similar changes to Gli3-/- TEC, 
and opposite to Shh-/-, consistent with overall greater Hh 
pathway activation in Kif7-/- TEC.
Kif7-/- T-cell development in chimeric mice
TEC provide MHC+peptide ligands to developing 
T-cells for positive and negative selection of the TCR 
repertoire and differentiation to SP cell. Therefore, the 
reduction in the proportion of MHCII+ cTEC and mTEC, 
and the reduced density of cell surface MHCII molecules 
on mTEC could potentially account for those differences 
in T-cell development in the Kif7-/- thymus that are in 
processes that require TCR ligation by MHCII+peptide, 
such as levels of cell surface CD5 expression. To 
investigate this, we made radiation chimeras in which 
all T-cells were Kif7-/-, but TEC were Kif7+/+. We 
introduced Kif7-/- and Kif7+/+ fetal liver (FL) cells into 
sublethally irradiated adult Rag1-/- mice and measured 
cell surface expression of CD5 on thymocytes. Both Kif7-
/- and Kif7+/+ FL cells were able to seed the thymus and 
expand and the proportions of thymocyte populations were 
similar in the adult Rag1-/- thymus reconstituted with 
Kif7-/- cells compared to that with WT cells (Figure 6A-
6B). However, on DP, CD4SP and CD8SP cells the levels 
(MFI) of cell surface CD5 expression were significantly 
lower (Figure 6C-6D). Low cell surface CD5 expression 
is a marker for low TCR signal strength, and these 
experiments show that the reduction in cell surface CD5 
expression observed in the Kif7-/- thymus is the result of 
cell-intrinsic Kif7-deficiency in T-cells, rather than the 
result of lower expression of MHC+peptide ligands for 
TCR on developing thymocytes.
In the spleen and LN of the radiation chimeric 
mice, the proportions of CD4 and CD8 T-cells were 
similar between those reconstituted by WT or Kif7-/- FL 
(Figure 6E). As CD5 expression correlates with TCR 
signal strength we tested whether Kif7-/- T-cells activated 
normally on ligation of CD3 and CD28. We activated 
splenocytes from WT and Kif7-/- with anti-CD3 and anti-
CD28 monoclonal antibodies, and compared the levels of 
induction of activation markers CD69 and CD25. CD69 is 
an early activation marker, and at 24 hours after activation, 
its expression was significantly lower on Kif7-/- CD4 
T-cells than on their WT counterparts (Figure 6F). During 
T-cell activation, cell surface CD25 expression occurs 
after the increase in CD69 expression. At 24 hours, the 
percentage of cells that expressed cell surface CD25 was 
significantly lower in Kif7-/- CD4 T-cells and in Kif7-/- 
CD8 T-cells than in their WT counterparts (Figure 6F). 
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This continued at 48 hours after activation, in both CD4 
and CD8 T-cell populations (Figure 6G). Thus, T-cell 
intrinsic Kif7-deficiency decreased the ability of T-cells to 
activate in response to CD3 and CD28 ligation. 
DISCUSSION
Here we showed that Kif7 is required for normal 
T-cell development and MHC expression on TEC in the 
fetal thymus. On E16.5, Kif7-deficiency increased the 
DN2 population, but led to reduced differentiation from 
DN to DP cell. Examination of the transition from DP to 
SP cell, also showed delayed differentiation to CD8SP, 
and reduced cell surface CD5 expression, indicative of 
defective positive selection. Interestingly, Kif7-deficiency 
also impacted on TEC, and led to lower cell surface 
MHCII expression on mTEC and cTEC.
Overall, these changes are consistent with the Kif7-
/- thymus having a higher level of Hh pathway activation, 
and indeed Ptch1 expression was higher in Kif7-/- 
thymocytes than WT, with Kif7 thus acting as a negative 
regulator of Hh pathway activation. In fact, at early stages 
Figure 6: T-cell development and activation in irradiated chimeric mice. In all bar charts in this figure, error bars show the 
standard error of the mean (SEM). A.-G. Radiation chimeras were made by transplantation of E18.5 Kif7-/- (n = 3) and WT (n = 3) fetal 
liver (FL) cells into sublethally irradiated Rag1-/- mice. A. Dot plots: anti-CD4 and anti-CD8 staining on thymocytes transplanted with WT 
(left) and Kif7-/- (right) fetal liver cells, giving the percentage in each quadrant. B. As in A, gated on CD3hi. C. Scatter plot: MFI of anti-
CD5 staining on CD3hi DP, CD4SP and CD8 SP populations from Rag1-/- transplanted with Kif7-/- (open circles) and WT (solid circles) 
fetal liver cells. Each point represents a mouse. Line shows the mean. The differences between the mean between chimeras made with WT 
and Kif7-/- fetal liver were significant for CD4SP, **p < 0.005; and for CD8SP, *p = 0.048. D. Relative mean MFI of CD5 staining as in 
C; for DP and CD4SP ***p < 0.0005; for CD8SP, *p < 0.01. E. Dot plots show anti-CD4 and anti-CD8 staining from radiation chimeras 
made form WT and Kif7-/- fetal liver, on spleen (left-hand plots) and LN (right-hand plots), giving the percentage of cells in the regions 
shown. (F-G) Scatter plots show the percentage of CD69+ cells and CD25+ cells in the CD4 T-cell population (left-hand plot) and CD8 
T-cell population (right-hand plot) when splenocytes from radiation chimeras made with WT (closed circles, n = 3) and with Kif7-/- (open 
circles, n = 3) were activated in vitro with anti-CD3 and anti-CD28 treatment, after 24 hours F. and 48 hours G. Each circles represents the 
reading from a culture from a different chimeric mouse. Means are shown with a line, and differences were statistically significant between 
WT-chimeras and Kif7-/- chimeras: At 24 hours, *p = 0.034 for CD69 on CD4 T-cells; **p = 0.009 for CD25 on CD4 T-cells; *p = 0.047 
for CD25 on CD8 T-cells. At 48 hours, *p = 0.037 for CD25 on CD4 T-cells; *p = 0.041 for CD25 on CD8 T-cells. 
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of T-cell development, Kif7-deficiency led to the opposite 
phenotype to deficiency in Shh and positive regulators 
of the pathway, as Smo-, Gli2- and Shh-deficiency all 
decrease the DN2 population[5, 14, 17]. At the pre-
TCR dependent transition to DP cell, Kif7-deficiency 
has a similar impact to Gli3-deficiency, with slower 
differentiation to DP cell, but the opposite effect to Shh-
deficiency and Gli2-deficiency[17, 34]. Likewise, Kif7-
deficient TEC had a similar phenotype to Gli3-deficient 
TEC, and the opposite phenotype to Shh-deficient TEC, 
indicative of increased Hh pathway activation[13]. 
Interestingly, the Kif7-deficient thymus was 
less sensitive to addition of rShh than WT, and T-cell 
development was refractory to the effects of neutralisation 
of Hh proteins. In WT thymus neutralisation of Hh proteins 
promoted T-cell development: it increased the proportion 
of CD3hi cells, and increased maturation of both SP 
populations, in addition to its previously described effect 
to increase differentiation from CD3hiDP cell to CD4SP 
and CD8SP[20]. In contrast, neutralisation of Hh proteins 
in the Kif7-/- thymus had no impact on differentiation or 
maturation of the SP populations, indicating that Kif7 is 
required for interpretation of changes in the Hh signal by 
developing T-cells.
At the transition from DP to SP cell, T-cell 
development in the Kif7-deficient thymus seems to 
diverge from simply being the opposite of Shh-deficiency 
or Gli2-deficiency. Deletion of both Shh and Gli2 lead to 
increased differentiation from DP to SP and an increase 
in the CD4SP:CD8SP ratio, which is indicative of higher 
TCR signal strength [20, 35]. In the Kif7-deficient thymus, 
however, the differentiation of the CD8SP population was 
delayed, suggesting a specific role for Kif7 in this lineage. 
In ciliated cells, Kif7 is believed to regulate Gli 
activity by controlling the structure of the primary cilium 
[6]. However, T-cells lack primary cilia, and ciliary 
proteins are located in the immune synapse [23]. We 
found that cell surface CD5 expression was reduced in 
Kif7-/- thymocytes, in the fetal thymus and in FTOC, and 
this reduction was the result of thymocyte-intrinsic loss 
of Kif7. Levels of cell surface CD5 expression correlate 
with the strength of TCR signal transduction, and Shh-
treatment also lowers CD5 expression on thymocytes, 
and lowers TCR signal strength in mature T-cells [19-21]. 
Therefore, the fact that Kif7-deficiency led to reduced 
CD5 expression points to a possible link between the 
machinery of Hh and TCR signalling in T-cells, and to a 
role for Kif7 in the immune synapse. Interestingly, Kif7-
/- T-cells from radiation chimeric mice were less able to 
activate in response to CD3 and CD28 ligation than their 
WT counterparts, confirming a T-cell intrinsic role for 
Kif7 in TCR signal transduction. Hh pathway activation 
has previously been shown to modulate T-cell activation 
and TCR signal strength [20, 21, 36]. In the future, it will 
be important to investigate if the role of Kif7 in T-cell 
activation is a result of increased Hh pathway activation 
or if it is an Hh-independent function of Kif7 in TCR 
signalling. 
MATERIALS AND METHODS
Mice
Kif7+/- mice[8] were purchased from the Mutant 
Mouse Resource Research Center (MMRRC); Rag1-
/- mice from Jackson Labs; C57BL/6 mice from 
Harlan. Genotyping of Kif7 mutant mice by PCR 
was performed as described [37] with primers neo 
(5′-GCAGCGCATCGCCTTCTATCG-3′), exon 2 
(5′-GGCGGGACCGACACTTTGGG-3′), and intron 2 
(5′-CACCTGACATGGAGTGCTGACC-3′), generating 
a 302 bp product in WT and 197 bp product in knockout 
allele.
To make chimeric mice, fetal liver cells from 
Kif7+/+ and Kif7-/- E18.5 embryos were injected 
intraperitoneally into sublethally irradiated Rag1-/- mice 
and analysed 10-12 weeks later. 
Mice were bred and maintained on a C57BL/6 
background at UCL under UK Home Office regulations.
Cell sorting
Thymocytes from 6-8 week-old C57BL/6 WT 
mice were stained with anti-CD25, anti-CD44, anti-CD3, 
anti-CD4 and anti-CD8 and sorted on a Modular Flow 
Cytometer (MoFlo; Cytomation, Fort Collins, CO) at ICH 
flow cytometry facility to obtain DN1 to DN4, DP and SP 
populations.
Quantitative RT-PCR
RNA was extracted from the sorted thymocytes 
using Absolutely RNA miniprep kit (Stratagene, La 
Jolla, CA), and cDNA synthesized with Superscript II 
(Invitrogen, Carlsbad, CA). cDNA samples were analyzed 
in triplicate by quantitative PCR on an iCycler (Bio-Rad) 
using SYBR Green Supermix (Bio-Rad) according to 
manufacturer’s instruction. Kif7 and Hprt primers were 
purchased from Quantitect Primer Assays (Qiagen) and 
Ptch1 primers were as described [37].
Flow cytometry and antibodies
Cell suspensions were prepared by crushing tissue 
between frosted glass slides. Cells were stained as 
described [37], using combinations of directly conjugated 
antibodies: anti-CD3, anti-CD4, anti-CD5, anti-CD8, anti-
CD24, anti-CD25, anti-CD44, anti-CD45, anti-CD69, 
anti-MHCI, and anti-MHCII (Ebioscience). 
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Samples were washed in staining buffer prior to 
acquisition on an Accuri C6 (Becton Dickinson) and 
analysed using Flowjo 10.1r5 (Tree Star, US). Live cells 
were gated by SSC and FSC, gating on singlets using 
Flowjo (FSC-A v FSC-H). 
Fetal thymus organ culture (FTOC)
FTOC was cultured for 7 days using E16.5 or E18.5 
fetal thymus as described [38]. For experiments shown in 
Figure 5, one lobe of each E16.5 WT or Kif7-/- thymus 
was cultured untreated (control) and the other lobe 
cultured in the presence or absence of rShh or rHhip as 
described [13, 19]. 
T-cell activation experiments
Splenocytes were isolated and stimulated with 
soluble 0.01μg/ml of anti-CD3 and anti-CD28 as described 
[20]. Cells were harvested at 24 and 48 hours and analysed 
by flow cytometry for cell surface markers of activation.
Isolation and staining of thymic epithelial cells 
(TEC)
TEC were isolated as described [13] from E16.5 
FTOC cultured for 5 days to allow differentiation of TEC 
lineages. After isolation, cells were stained with anti-
CD45APCcy7 as a haematopoitic lineage marker and anti-
Epcam1PEcy7, to identify the total TEC population (CD45-
Epcam1+). Identification of mTEC and cTEC populations 
were identified as staining positive with anti-UEA-1Fitc 
and anti-Ly51PE, respectively. Samples were acquired on 
a LSR-II (Becton Dickinson) and analysed using Flowjo 
10.1r5 (Tree Star, US).
Microarray and data analysis
Microarray analysis was carried out as described 
[38] on RNA from Facs sorted cTEC and mTEC from 
fetal and adult WT C57BL/6 mice [18]. TEC populations 
were isolated and sorted as described [13]. The data 
analysis was carried out as described [38]. The data are 
publicly available in http://www.ncbi.nlm.nih.gov/ . GEO 
reference: GSE81433. 
Statistical analysis
Statistical analysis was performed using unpaired 
two-tailed t-tests or ANOVA and probabilities considered 
significant if P≤0.05 (*), P≤0.01 (**) and P≤0.001 (***). 
All experiments were carried out at least three times 
(independent experiments with biological replicates). 
Error bars represent SEM.
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